Pharma BD Deal Intelligence

Biogen Inc. / Alcyone Therapeutics, Inc.

2025 · Acquisition/Merger · $85M · Complete

Biogen agreed to acquire Alcyone Therapeutics for an upfront cash payment of USD 85 million plus development and regulatory milestone payments tied to ThecaFlex DRx with nusinersen and additional pipeline products. The deal secures all rights to ThecaFlex DRx, an implantable subcutaneous port and catheter system for intrathecal delivery of antisense oligonucleotides, extending an existing Biogen-Alcyone partnership.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals  ·  Biogen Inc. deals